Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PAD regimen in relapsed or refractory multiple myeloma
2005-000395-41Phase 2Unknown
- Sponsor
- Cancer Trials Ireland
- Start
- May 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Overall response rate (CR + PR) to PAD therapy. Status: unknown.
02
Drugs
bortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-000395-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000395-41.